Yi Shen

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 520 citations

Medicine, Pathology, Gefitinib Versus Vinorelbine +8

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Dongsheng Yue, Shidong Xu, Qun Wang et al. · The Lancet Respiratory Medicine · 2018 · 288 citations

Medicine, Pathology, Erlotinib Versus Vinorelbine +8

Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer

Dongfang Tang, Yi Shen, Mingzhao Wang et al. · European Journal of Cancer Prevention · 2013 · 132 citations

Immunology, Pathology, Plasma Micrornas +18

The Shh/Gli signaling cascade regulates myofibroblastic activation of lung-resident mesenchymal stem cells via the modulation of Wnt10a expression during pulmonary fibrogenesis

Honghui Cao, Xiang Chen, Jiwei Hou et al. · Laboratory Investigation · 2019 · 76 citations · Full text

Pulmonary Fibrogenesis, Fibrosis, Developmental Biology +10

The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

Junjie Xi, Wen‐Zhao Zhong, Weimin Mao et al. · Journal of Thoracic Oncology · 2018 · 72 citations

Oncology, Adjuvant Trial, Adjuvant Gefitinib Therapy +9